| Compound | Cagrilintide + Semaglutide (CagriSema) |
|---|---|
| Category | Amylin analog + GLP-1 agonist combination |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Cagrilintide + Semaglutide (CagriSema) — a amylin analog + glp-1 agonist combination — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
An investigational fixed-dose combination pairing the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide, designed to engage complementary satiety and incretin pathways in a single weekly injection.
Mechanism of Action
The combination pairs amylin-receptor-mediated satiety and gastric effects with GLP-1 receptor-driven appetite and glycemic control. Whether the mechanisms are merely additive or partially synergistic is one of the questions the phase 3 program is designed to answer.
Research and Evidence
Phase 3 trials in obesity have reported mean weight reductions exceeding 20% at the highest combination dose, among the largest reported for any investigational metabolic therapy. Regulatory review is ongoing in multiple jurisdictions.
Safety and Side Effects
The tolerability profile reported to date is dominated by nausea and other gastrointestinal effects, consistent with both parent mechanisms. Definitive safety labeling awaits approval decisions.
Frequently Asked Questions
What is the evidence tier of Cagrilintide + Semaglutide (CagriSema)?
Cagrilintide + Semaglutide (CagriSema) is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Cagrilintide + Semaglutide (CagriSema) an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Cagrilintide + Semaglutide (CagriSema)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered CagriSema studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.